Mira Hellmann, MD, discusses using trametinib to treat patients with low-grade ovarian serous carcinomas.
Mira C. Hellmann, MD
Advertisement
Articles by Mira C. Hellmann, MD
Mira C. Hellmann, MD, discusses the benefit of PARP inhibitors in patients with ovarian cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
Routine Breast Imaging May Offer Little Benefit After Double Mastectomy for Early Breast Cancer
3
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
4
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
5